1. Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study
- Author
-
Lionel Ades, Véronique Mansat-De Mas, Benoit de Renzis, Zahia Azgui, Laurent Knoops, Odile Beyne-Rauzy, Pierre Fenaux, Aurélie Cabrespine, Jean-Jacques Kiladjian, Eric Wattel, UCL - (SLuc) Service d'hématologie, and UCL - SSS/DDUV - Institut de Duve
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Case-control study ,Hematology ,Bioinformatics ,Prognosis ,JAK2V617F mutation ,Internal medicine ,hemic and lymphatic diseases ,Mutation (genetic algorithm) ,Overall survival ,medicine ,MDS ,Favorable outcome ,Good prognosis ,Jak2v617f mutation ,AML progression ,business ,Brief Communications ,RARS-T - Abstract
While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. JAK2V617F mutation was significantly correlated with lower progression to AML (p
- Full Text
- View/download PDF